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Abstract Several aspects of the development of competitive
lateral flow immunoassays (LFIAs) are described. The
quantitation of progesterone is taken as an example. The
LFIA format consisted of a nitrocellulose membrane spotted
with various progesterone conjugates as the test line. A
mixture of primary antibody and secondary antibody adsorbed
to colloidal carbon was used for signal generation. A digital
scanner and dedicated software were used to quantitate the
response. A reappraisal of the checkerboard titration, often
used in the optimisation of immunoassays, is discussed.
Surprisingly, the highest sensitivity of the LFIA format (IC50
of 0.6 µg L−1 progesterone in buffer) was achieved by using
a high coating concentration of the analyte–protein conjugate
and a high dilution of the antibody solution. Immediate
addition of all reagents in LFIA was superior to premixing
the components and allowing prereaction. Of several block-
ing agents tested bovine serum albumin was superior in
performance, whereas the combination of ovalbumin and
progesterone substantially influenced test results.
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Introduction
Lateral flow immunoassays (LFIAs) are currently a versatile
and therefore popular assay format, especially for applica-
tions outside the laboratory, i.e. “point of care/need”
applications. LFIA is a one-step assay that is easy to
perform, fast and cheap. Major advantages of LFIA are that
no trained personnel or expensive apparatus is necessary.
Furthermore, prepared strips can be stored for a long time
without refrigeration, giving this method a fair chance in off-
laboratory or resource-poor settings. A literature survey of
the technique and a discussion of the strengths, weaknesses,
opportunities and threats (a SWOT analysis) can be found
elsewhere [1]. Primary anti-analyte antibody and labelled
secondary anti-species antibody are used for recognition
and signal generation. A test line of analyte–protein
conjugate and a control line of anti-animal species antibody
of the labelled antibody are sprayed onto plastic-backed
membranes. A sample application pad and a conjugate
release pad are applied to one end of the strip and an
absorbent pad is applied at the distal end of the strip (cf.
Fig. 1a). The absorbent pad wicks the fluid sample through
the membrane. At the conjugate release pad, dried primary
antibody and labelled secondary antibody are applied.
Introduction of the sample onto the sample pad initiates
the test.
Despite generally wide use [1], LFIAs for progesterone
in the milk of diary animals have not been commercialized
yet. The aim of the present investigation is to optimise the
conditions to quantitate progesterone using a dry reagent
immunoassay format.
When the analyte is a hapten, the design is restricted to
the competitive format. In this format free antigen and
immobilized antigen compete for a limited amount of
antibody binding sites. When developing such an assay
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format a first screening is commonly used to find the
optimal concentrations of antibody and antigen by a
checkerboard titration [2]. However, another approach has
been proposed using the total internal reflectance fluores-
cence (TIRF) technology [3–6], but that has not been
explored practically when developing enzyme-linked im-
munosorbent assays (EIAs) or LFIAs. According to the
latter studies a sensitive assay requires that the amount of
antigen bound on the surface is high, which also enables a
high dilution of the antibody. Using this strategy, the
response at the chip is mass-transport-limited and not
dependent on the kinetics of binding of antibody to
antigen.
We report here on a reappraisal of the checkerboard
titration in the development of competitive EIA and LFIA
test formats. To this end, we used combinations of several
monoclonal antibodies, raised against different analyte–
protein conjugates. A combination with several coating
conjugates was applied. In addition, we present some other
aspects of the development of competitive LFIAs, such as
the sequence of addition of sample and reagents and the
influence of the blocking agent. Progesterone (P4) was
chosen as the model hapten (cf. Fig. 1b).
Experimental
Reagents
Progesterone (pregn-4-ene-3,20-dione, P4), bovine serum
albumin (BSA), chicken egg-white serum albumin (OVA)
and thimerosal (2-(ethylmercuriomercapto)benzoic acid sodi-
um salt) were purchased from Sigma-Aldrich Chemie BV
(Zwijndrecht, the Netherlands). Lactoferrin was from DMV
International (Veghel, the Netherlands), β-lactoglobulin was
from Davisco (Geneva, Switzerland), and polyvinlylpyrroli-
done (30 kDa), poly(methyl-vinylether-10-maleic anhydride)
and teleostean gelatin were from Biodot Inc. (Irvine, CA,
USA). All related steroids and steroid–BSA conjugates
were purchased from Steraloids, Inc. (Newport, RI, USA),
cf. Table 1. NH2-functionalized biotin with different
length poly(ethylene oxide) linkers and neutravidin were
from Pierce (Perbio Science Nederland BV, Etten-Leur,
the Netherlands). Goat-anti-mouse IgG-fc-specific in the
LFIA as secondary antibody was from Jackson Immuno-
research Europe (Sanbio, Uden, the Netherlands), and goat-
anti-mouse IgG conjugated to horseradish peroxidase (HRP)
as secondary antibody in the EIA was purchased from
DAKO Diagnostics (Heverlee, Belgium). Other chemicals
were of the highest purity available and purchased from
Merck (Amsterdam, the Netherlands). Water was of Milli Q
quality (Millipore, Amsterdam, the Netherlands).
Materials and instruments
Enzyme-linked immunosorbent assay
Costar 3590 high-binding 96-well microplates were pur-
chased from Corning BV Life Sciences (Schiphol-Rijk, the
Netherlands). For the tests using antibodies raised with P4
conjugates without BSA all solutions contained BSA for
blocking, otherwise OVA was used.
The tests were performed essentially as described in ref.
[7] with slight modifications as described in ref. [8]. In
anticipation of the final assay format being the LFIA,
antibody incubation times were reduced to 10 min. Briefly,
P4 conjugated to BSA or OVAwas coated overnight at 4 °C
or 1 h at 37 °C in high-binding microplate wells. When
using the P4-HS–PE2-biotin or P4-HS–PE3-biotin conju-
gates, a mixture of neutravidin and conjugated P4 was
coated in the wells. The neutravidin/biotin molar ratio was
1:3.4. After blocking, a mixture of 50 µL of serial dilutions
Fig. 1 Schematic of a lateral
flow immunoassay test format
and a model of the progesterone
molecule: a schematic setup of
an inhibition LFIA (not to
scale), showing the response
when no analyte is present (up-
per panel) or when analyte is
present (lower panel); b model
of the progesterone molecule, a
representation in pdb format and
the numbering of C atoms in the
steroid part of the molecule,
where the keto group at position
3 and two methyl side chains at
positions 10 and 13 were re-
moved for clarity
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of a P4 standard followed by 50 µL of an appropriate
antibody dilution in assay buffer were allowed to compete
with immobilized P4 conjugate. After incubating and
washing, secondary antibody coupled to HRP was added
and reacted for 10 min. After washing to remove excess
label, substrate solution was added to the wells, and the
enzyme reaction was stopped after a predetermined time by
addition of 2 mol L−1 H2SO4. Absorbance values (A450)
were measured with a Wallac Victor 1420 Multilabel
Counter (PerkinElmer, Wellesly, MA, USA).
Table 1 Overview of COOH-functionalised progesterone haptens and NH2-biotin-poly(ethylene oxide) reagents
Progesterone 3-CMO Progesterone-17-ol-3-CMO
Progesterone 11α-HS Progesterone 21α-HS
Progesterone 6β-HS Progesterone-7α-CET
Biotin PE2 Biotin-PE3
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Abbreviations: CET carboxyethylthioether, CMO carboxymethyloxime, HS hemisuccinate, PE2 two poly(ethylene oxide) moieties, PE3 three poly
(ethylene oxide) moieties
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Lateral flow immunoassay
Costar 3595 low-binding 96-well microplates were pur-
chased from Corning BV Life Sciences (Schiphol-Rijk, the
Netherlands). For the initial tests using antibodies raised
with P4 conjugates without BSA all solutions contained
BSA for blocking, otherwise OVA was used, except for the
tests on blocking agents. Tests were performed essentially
as described in ref. [9]. Briefly, the P4–protein conjugate
solution in spraying buffer (1 µL/strip) was spotted
using a TLC spotter (Camag Linomat IV, Camag, Berlin,
Germany) at an amount ranging from 7 to 1,000 ng/strip
on plastic-backed nitrocellulose membranes with a pore
size of 12 µm, AE100 (Whatman/Schleicher and Schuell,
‘s-Hertogenbosch, the Netherlands). When using the P4-
HS–PE2-biotin or P4-HS–PE3-biotin conjugates, a mixture
of neutravidin and conjugated P4 was sprayed on the strips
at the test line. The neutravidin/biotin molar ratio was 1:3.4.
The membranes were dried overnight at 37 °C. A second
plastic backing was applied and the membranes were cut
into 0.5×5 cm strips using a Biodot CM4000 cutter (Biodot
Inc., Irvine, CA, USA). An absorption pad of cellulose was
applied (Whatman/Schleicher and Schuell, ‘s-Hertogenbosch,
the Netherlands) to the prepared membranes which were then
stored desiccated in the dark at room temperature.
In low-binding microplate wells 50 µL of sample was
mixed with 50 µL of an appropriate dilution of primary
antibody and 10 µL of a 1:10 dilution of carbon-labelled
secondary antibody (0.2 g L−1 carbon nanoparticles) in
running buffer. A test strip was positioned vertically in
the well containing this mixture and the test solution was
allowed to run. After complete drying the pixel grey
volume of the test line was recorded using an Epson 3200
Photo scanner (Seiko Epson, Nagano, Japan) and dedicated
software. Scans were performed at 1,200-dpi resolution
using 16-bit grey scale. The resulting images were saved as
16-bit TIFF files and processed by image analysis software
(TotalLab, Nonlinear Dynamics, Newcastle upon Tyne,
UK). Essentially, the software records the grey level of
every pixel in the picture frame as indicated by the user on
a scale of 0–255 and integrates the data of all pixels. Blank
pixel grey volume on every individual strip was measured
just below the test line and subtracted from the pixel grey
volume of the test line. Images used for Fig. 4b were
cropped and modified by applying the “sharpen” function
in Photoshop 5 (Adobe Systems Inc., San Jose, CA, USA).
No other modifications were applied.
For experiments on maximal performance and reproduc-
ibility of the LFIA tests, several protocols for the addition
sequence of reagents were used according to Scheme 1.
These tests were performed twice in triplicate.
Solutions
The coating buffer comprised 0.95 g Na2CO3 and 44 g
NaHCO3 in 1 L H2O, pH 9.6. Phosphate-buffered saline (PBS)
comprised 1.265 g NaH2PO4·H2O, 12.10 g Na2HPO4·12H2O,
8.5 g NaCl and 0.2 g thimerosal in 1 L H2O, pH 7.2. Assay
buffer comprised PBS with 1.0 g blocking agent in 1 L,
pH 7.2. Spraying buffer comprised 5 mmol L−1 boric acid/
sodium tetraborate, pH 8.5; running buffer comprised
0.1 mol L−1 boric acid/sodium tetraborate, 10 g L−1 blocking
agent, 0.5 mL L−1 Tween20 and 0.2 g L−1 NaN3, pH 8.5.
Monoclonal antibodies
A monoclonal antibody against P4-11α-hemisuccinate–
bovine thyroglobulin (11-BTG) was developed in mice
under supervision of the Animal Sciences Group of
Wageningen UR (ASG-WUR, Lelystad, the Netherlands)
in accordance with the Institute’s ethical guidelines in
collaboration with MCA Development (Groningen, the
Netherlands). Hybridomas were produced as described by
Fazekas de St. Groth and Scheidegger [10] and the
hybridoma cell line that secreted an antibody against P4
was selected resulting in the mAb 49.3. This mAb exhibited
high affinity to P4 (D.F.M. van de Wiel, ASG-WUR;
personal communication). Supernatant was purified by
affinity chromatography on ProteinA-Sepharose. Aliquots
of the mAb in a solution of 0.9 g L−1 in 500 g L−1 glycerol/
PBS were stored at −20 °C. The antibody was thoroughly
characterized in relation to cross-reactivity to related
steroids in the EIA format where the progesterone-7α-
CET–BSA conjugate was coated in the microplate wells.
The level of cross-reactivity was determined by comparing
the 50% inhibition concentration of progesterone with 50%
inhibition concentration of the competing compound. To
this end a standard curve of progesterone with serial
dilutions (1:1) in the range of 1–100 µg L−1 and serial
dilutions (1:10) of the competing compound in the range of
Protocol # Sequence of addition of sample and reagents 
1 All reagents were added immediately to sample. 
2 Pre-incubation of sample and primary antibody for 30 min. 
3 Pre-mixing of primary and secondary antibody, immediate addition to sample. 
4 Pre-incubation of primary and secondary antibody for 30 min. 
Scheme 1 Protocols for reagent
addition in LFIA format
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1–10,000 µg L−1 were used. Goat-anti-mouse coupled to
HRP was used as the secondary antibody.
Several commercially available monoclonal purified
mouse antibodies raised against P4-11α-HS–BSA (11-BSA)
were purchased: M630408 (Fitzgerald Industries Internation-
al, Concord, MA, USA), P2PXM207 (Acris Antibodies
Hiddenhausen, Germany) and 4P01 (LabVision/Neomarkers,
Immunologic, Duiven, the Netherlands). Cross-reactivity of
monoclonal antibody 4P01 with related steroid compounds
was reported in ref. [11] in microplate format.
Antigen conjugates
A conjugate of P4-11α-HS (Steraloids, Newport, RI, USA)
with OVA was prepared by using the Imject Immunogen
EDC Kit with OVA (Pierce, Perbio Science Nederland,
Etten-Leur, the Netherlands). The protein conjugate was
dialyzed against Milli Q water using a membrane with cutoff
value of 15 kDa and lyophilised (P4-11α-HS–OVA). A
conjugate of P4-11α-HS and OVA was also obtained from
the Weizmann Institute, Rehovot, Israel (P4-11α-HS–OVA).
Conjugates of P4-HS to PE2-biotin or PE3-biotin (Pierce,
Perbio Science Nederland, Etten-Leur, the Netherlands)
were prepared by the mixed anhydride method [12] with
minor modifications. P4-HS–PE2-biotin and P4-HS–
PE3-biotin conjugates were purified using a preparative
HPLC system with mass detection (Waters Corp., Milford,
MA, USA) and fractions with the required mass were
lyophilised. All conjugates were stored desiccated at −20 °C
in the dark.
Statistics
Calculations of best-fit formulae, IC50 values (i.e. the con-
centration at 50% of the blank signal) and design of graphs
for Figs. 2, 4a and 5 were done using the program Microcal
Origin version 6.0 (Microcal Software Inc., Northampton,
MA, USA). The percentage of cross-reactivity is defined as the
IC50 of progesterone divided by the IC50 of the related steroid
times 100%. The program Microsoft Excel 2000 (Microsoft
Nederland BV, Amsterdam-Z.O., the Netherlands) was used
to calculate the SD and SEM data, and to prepare Fig. 3.
Results and discussion
Characterization of the monoclonal antibody mAb 49.3
The monoclonal antibody mAb 49.3 was thoroughly
characterized with respect to cross-reactivity using the EIA
format. A high degree of cross-reactivity was found with
11α-hydroxyprogesterone (not shown). This is not unex-
pected because the antibody was produced by hybridomas
from mice immunized against progesterone-11α-HS–BTG.
An acceptable level of cross-reactivity was found for the
other steroid compounds tested (Table 2).
Enzyme-linked immunosorbent assay
Preliminary tests were used in a checkerboard titration to
determine optimal concentrations of the antibody and the
P4 conjugate under consideration. Several combinations
performed well, whereas, to our surprise, the mAb M630408
using OVA as blocking agent did not give a satisfactory
response with any of the antigen conjugates (not shown). At
that time this observation was not understood, but later on
the effect of the OVA used as blocking component became
clear (cf. Influence of blocking agents on the response).
This might have been the reason for the unsatisfactory
performance of this mAb with all antigen–conjugate
combinations tested.
In a standard checkerboard titration experiment, the best
performance was obtained using P4-7α-CET–BSA at a
coating concentration of 33 µg L−1 and a 1:1,800 dilution
of the antibody mAb 49.3 preparation. Application of the
strategy as mentioned in ref. [5] is depicted in Fig. 2. The
antibody dilution was chosen in such a way that the blank
signal was always at an A450 of 1.5. As a typical example
the response of mAb 49.3 using P4-7α-CET–BSA is shown
for assay buffer containing 1 g L−1 BSA spiked with serial
dilutions of P4 and low or high coating concentrations and
mAb dilutions. The IC50 of the standard curve when using a
coating concentration of 33 µg L−1 was 2.4 µg L−1, whereas
an IC50 of 0.4 µg L
−1 was obtained for the curve resulting
Fig. 2 Typical example of the sensitivity of the assay in the
microplate EIA, given as the B/B0 at 450 nm. Recognition was
performed with mAb 49.3. Dashed line coating concentration of
33 µg L−1 P4-7α-CET–BSA, solid line coating concentration of
10 mg L−1 with the same conjugate. The antibody dilution was chosen
in such a way that the blank signal was always at an A450 of 1.5. SDs
were typically below 10%
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from the incubation at a coating concentration of
10 mg L−1. The better sensitivity of the assay with a high
coating concentration is in-line with another study [5],
which showed similar results for an immunosensor for the
quantitation of P4 in buffer and bovine milk.
Surprisingly, although the mAb P2PXM207 showed a
good performance in the checkerboard titration using OVA
allowing a high antibody dilution, no inhibition was seen
when serial dilutions of P4 in the required concentration
range were applied.
Lateral flow immunoassay
Influence of the sequence of addition of reagents
and sample
Tests were done to reveal the influence on the performance
of the LFIA with respect to the sequence of addition of
reagents and sample and, possibly, preincubation. Immedi-
ate mixing of all reagents (protocol 1), favourable for a
simple and fast assay, was found to be superior to the other
protocols (cf. Fig. 3), with an intra-assay SD of 1–20% and
an interassay SEM of 20–30%. For the other protocols an
intra-assay SD of 10–60% and an interassay SEM of 20–
40% were calculated.
Influence of coating concentration
In a preliminary checkerboard titration the responses of
antibody–antigen combinations were screened. The mono-
clonal antibody mAb 49.3 recognized all P4 conjugates,
indicating a more general antigenic interaction (cf. Table 3).
In addition, the Neomarkers mAb 4P01 was exclusively
tested in this format. This mAb performed best when using
the P4-3-CMO–BSA coating conjugate. However, there was
no recognition when using the P4-6β–PE2-biotin, P4-6β–
PE3-biotin and P4-7α-CET–BSA conjugate (cf. Table 3).
For this antibody, the antigenic determinant is anticipated at
the C-3, C-11 and/or C-21 moieties (cf. Fig. 1b).
In a standard checkerboard titration experiment, the best
performance was obtained using P4-7α-CET–BSA at a
coating concentration of 125 ng µL−1 and a mAb 49.3
concentration of 2.5 ng mL−1. It was not clear from the
checkerboard titration tests performed in this format that,
due to the different kinetics, the relationship between a high
coating concentration and consequently a high dilution of
the antibody as stated in ref. [5] was valid here as well.
Application of this strategy in an inhibition assay is depicted
in a typical example using mAb 49.3 and P4-7α-CET–BSA
in Fig. 4a. The mAb concentration was chosen in such a
way that the response of a buffer solution without P4 was
always at a pixel grey volume of 1×105, a value that can be
clearly seen by the naked eye. The IC50 with a coating
concentration of 125 ng µL−1 was, as obtained from the
standard curve, 5.5 µg L−1, and with a coating concentra-
tion of 1,000 ng µL−1 the IC50 was 1.2 µg L
−1. A similar
response was observed when mAb 4P01 and P4-3-CMO–
BSA were used with BSA as blocking agent (results not
shown). Using this latter combination an IC50 of 2.7 µg L
−1
with a coating concentration of 62.5 ng µL−1 was obtained,
whereas at a coating concentration of 1,000 ng µL−1 an
IC50 of 0.6 µg L
−1 was obtained. No inhibition was seen
with OVA as blocking agent. An example of an inhibition
assay on the strips is depicted in Fig. 4b.
In a typical inhibition experiment with the P4–PE
conjugates it can be concluded that the binding of the
antibody mAb 49.3 and mAb 4P01 to the conjugate at the
11-position is strongest, as these antibodies were raised
with a similar P4–protein conjugate. As a consequence,
the competition with free P4 is less sensitive (cf. Table 4).
These results are in accordance with earlier observations
Table 2 Cross-reactivity of the monoclonal antibody mAb 49.3 in the
EIA format
Steroid Cross-reactivity (%)a
Progesterone 100
Cortisol 0.04
Corticosterone 0.5
Estrone 0.03
Estradiol < 0.03
Pregnenolone < 0.03
5α-Pregnane-3,20-dione 0.3
a Cross-reactivity is defined as the IC50 of progesterone divided by the
IC50 of the related steroid times 100%
Fig. 3 Response of 0 µg L−1 (light grey), 10 µg L−1 (dark grey) or
50 µg L−1 P4 (black) on different protocols of sequence of addition of
reagents. Protocol 1 immediate addition of all reagents to the sample,
protocol 2 preincubation of sample with primary antibody, protocol 3
premixing of primary and secondary antibodies, protocol 4 preincu-
bation of primary and secondary antibodies
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[13–15]. A slight tendency for a better sensitivity with the
longer spacer can be observed. This is in agreement with
the results reported in ref. [16]. However, due to the
hygroscopic nature and consequently the difficulty in
handling, these conjugates were not used in subsequent
experiments.
Influence of blocking agents on the response
To our surprise, the monoclonal antibodies Acris P2PXM207
and Neomarkers mAb 4P01, both raised with P4-11α-HS–
BSA and both allowing a high dilution in the checkerboard
titration, did not show any inhibition when using OVA as
blocking protein. This phenomenon was seen in the EIA and
LFIA formats. In a study using a TIRF format [6], OVA
was also used as a blocking agent with mAb BM2068.
However, this antibody is no longer available, and the
authors advised P2PXM207 instead (Dr N.D. Käppel,
Eberhard-Karls-University of Tuebingen, personal commu-
Fig. 4 a Typical example of the sensitivity of the assay in the LFIA
format using mAb 49.3 and P4-7α-CET–BSA: dashed line coating
concentration 125 ng µL−1, solid line coating concentration
1,000 ng µL−1. b Scan of LFIA strips in an inhibition assay on P4
using mAb 4P01 and P4-3-CMO–BSA at a coating concentration of
1,000 ng µL−1. The antibody dilution was chosen in such a way that
the blank signal was always at a pixel grey volume of 1×105. SDs
were typically below 20%
Table 4 Sensitivity of preliminary LFIA test for several P4-PE–biotin
conjugates
Coating conjugate mAb 49.3 mAb 4P01
IC50
(µg L−1)
IC50 (µg L
−1)
P4-6β-HS–PE2-biotin 13 No recognition
P4-6β-HS–PE3-biotin 4 No recognition
P4-11α-HS–PE2-biotin 28 > 40
P4-11α-HS–PE3-biotin 24 21
P4-21-HS–PE2-biotin 7 13
P4-21-HS–PE3-biotin 7 10
A mixture of neutravidin and P4–biotin conjugate (molar ratio
neutravidin/biotin 1:3.4) was sprayed on the test line at a concentra-
tion of 500 ng µL−1 neutravidin
Table 3 LFIA format, response in checkerboard titration to different P4–protein conjugates on several antibodies
Coating conjugate Immunogen (antibody; brand)
11-BTG (mAb 49.3; ASG-WUR)a 11-BSA (mAb P2PXM207; Acris)b 11-BSA (mAb 4P01; Neomarkers)a
P4-3-CMO–BSA ++ ++ ++
P4-3-CMO-17-ol–BSA ++ ++ ++
P4-7α-CET–BSA ++ ++ –
P4-21-HS–BSA ++ NT ++
P4-11α-HS–OVA ++ ++ ++
P4-6β-HS–biotin-PE2 ++ NT –
P4-6β-HS–biotin-PE3 ++ NT –
P4-11α-HS–biotin-PE2 ++ NT ++
P4-11α-HS–biotin-PE3 ++ NT ++
P4-21-HS–biotin-PE2 ++ NT ++
P4-21-HS–biotin-PE3 ++ NT ++
++ good response, – no response, NT not tested
a Blocking with 10 g L−1 BSA in running buffer
b Blocking with 10 g L−1 OVA in running buffer
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nication), but in this and a previous publication the OVA
concentration was not mentioned [5, 6].
To elucidate this discrepancy, OVA was also used to
perform an inhibition assay using mAb 49.3 that was not
raised using a conjugate with BSA and could be used with
BSA and/or OVA as blocking agent. When using this mAb
no inhibition was observed when using OVA as blocking
agent (result not shown). A preliminary test on the influence
of BSA as blocking agent using the Neomarkers mAb 4P01
revealed that in this format there was no serious interference
of BSA on the response (not shown). A series of BSA–OVA
combinations in running buffer were prepared, and using
monoclonal antibody mAb 49.3 or mAb 4P01 the influence
on the assay performance upon increasing concentrations of
OVAwas elucidated (cf. Fig. 5).
The results on OVA strongly suggest that OVA binds to the
P4 conjugate at the test line, or shields the P4 conjugate from
recognition by the antibody, since the blank signal, i.e. without
addition of 20 µg L−1 free P4, is strongly reduced upon
addition of OVA (cf. Fig. 5a and c). Moreover, the response
difference between the 0 µg L−1 and 20 µg L−1 P4 decreases
with higher OVA concentration, which also suggests an
influence of OVA on the binding of free P4 with the antibody
in solution (cf. Fig. 5b and d). Obviously, OVA has a binding
affinity or (antibody-)shielding propensity towards P4,
maybe due to a hydrophobic binding pocket or surface area.
Fig. 5 Dependency of the test
response on the OVA concen-
tration in running buffer:
a absolute response of blank
buffer on increasing OVA
concentration and decreasing
BSA concentration using
P4-3-CMO–BSA and mAb
4P01, b difference in response
between P0 (no P4) and P20
(20 µg L−1 P4) using
P4-3-CMO–BSA and mAb
4P01, c absolute response of
blank buffer on increasing OVA
concentration and decreasing
BSA concentration using
P4-7α-CET–BSA and mAb
49.3, d difference in response
between P0 (no P4) and P20
(20 µg L−1 P4) using
P4-7α-CET–BSA and mAb
49.3. SDs were typically
below 20%
Table 5 Influence of blocking agents on the progesterone-specific LFIA performance
Blocking agenta mAb 49.3/ P4-7α-CET
BSA Used as common blocking agent, complete inhibitionb
OVA Nearly no inhibitionb
β-Lactoglobulin Nearly no inhibitionb
Lactoferrin No recognition at the test line
Casein hydrolysate Speed reduction due to obstruction, nearly no inhibitionb
PVPc Less recognition at test line, smear on strip, nearly no inhibitionb
p(MVEMA)d Aggregation of label, no recognition at test line
TGe No recognition at test line
a A concentration of 10 g L−1 was used unless otherwise mentioned
b Inhibition with a concentration of 20 µg L−1 progesterone
cPVP polyvinylpyrrolidone, 30 kDa
d p(MVEMA) poly(methyl-vinylether-10-maleic anhydride), concentration 1 g L−1
e TG teleostan gelatin, concentration 1 g L−1
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The influence of several commonly used blocking
agents was tested in the LFIA format. In Table 5 a
summary of the results is given for mAb 49.3. BSA was
superior to the other blocking components. The mAb 4P01
behaved in a similar way (not shown). It is remarkable that
with β-lactoglobulin a similar phenomenon is observed as
with OVA, i.e. no inhibition by P4 at 20 µg L−1. In this case
it is tempting to assume a role comparable to the retinol
(vitamin A) binding pocket in β-lactoglobulin [17].
By using lactoferrin even the blank incubation, without
free P4, does not give a response, which indicates that this
protein prevents the binding of the antibody–carbon
conjugate to the capture antigen. Having a high isoelectric
point (approximately 8.7) the overall charge of this protein
in the incubation buffer is positive instead of negative, as is
the case for the other blocking agents. Whether this charge
difference is the explanation for the absence of a blank
signal remains to be elucidated. Other blocking agents like
casein hydrolysate, polyvinylpyrrolidone and poly(methyl-
vinylether-10-maleic anhydride) affect the performance
of the assay and, hence, are not preferred for blocking
purposes.
Conclusions
A monoclonal antibody to progesterone was obtained with
good sensitivity and specificity using progesterone-11α-
hemisuccinate–bovine thyroglobulin as immunogen. The
sensitivity of progesterone-specific EIAs and LFIAs was
increased by applying a high concentration of coating
conjugate and a high mAb dilution as reported before using
a progesterone-specific immunoassay with TIRF technolo-
gy [5]. For the LFIA format an IC50 of 0.6–1.2 µg L
−1
progesterone in buffer (depending on the antibody) could
be realized which has not been shown before for this
analyte in this assay format. Tests on the performance of the
LFIA format by changing the sequence of addition of the
sample and reagents, and without or with preincubation of
some of the reactants, revealed that addition of all the
reagents at once was superior. Fortunately, this order of
additions is favourable for a fast performance of this assay.
Addition of OVA as blocking agent was detrimental in both
progesterone-specific EIAs and LFIAs. Based on the results
with and without free progesterone we suggest that OVA
prevents binding of the antibody to the immobilized capture
antigen and/or binds to the immobilized capture antigen and
the analyte in solution. The presence of a hydrophobic binding
pocket on the protein could, however, not be confirmed.
Application of several other, commonly used blocking agents
gave no better performance than BSA. These results empha-
sise that only blocking agents that do not interact with the
specific antibody and/or antigen should be used.
Often LFIAs allow direct application of bodily fluids
such as saliva, blood and urine [1]. Our focus was on bovine
milk, but then additional sample pretreatment appeared to
be required to assay progesterone with an LFIA format. We
found that solid-phase extraction might give sufficient
purification [18], but more effort is necessary to implement
this idea in an off-laboratory LFIA test. Finally, validation
of a progesterone-specific LFIA with other quantitative
methods (e.g. GC–MS [19] or LC–MS [20] and a validated
EIA [13]) is required before routine use.
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